Skip to main content

PTC Therapeutics, Inc.

corporate_fare Company Profile

PTC Therapeutics, Inc.

PTCT·NASDAQ·Life Sciences·CIK 0001070081

PTC THERAPEUTICS, INC. is a global biopharmaceutical company focused on discovering, developing, and selling specialized medicines for children and adults with rare disorders. The company aims to provide access to treatments for patients with unmet medical needs by using its scientific knowledge and global sales network. PTC THERAPEUTICS has a diverse range of therapeutic products, including several that are already on the market and others in various stages of development, from early discovery to clinical trials. These efforts are concentrated on creating new treatments for rare neurological and metabolic diseases. As of the report date, the company's significant commercial products and clinical-stage programs include: Sephience (sepiapterin): This product treats adult and pediatric patients with phenylketonuria (PKU), a rare inherited metabolic disease. PKU prevents the body from breaking down phenylalanine (Phe), which can lead to neurological issues. Sephience works through a dual mechanism to reduce blood Phe levels and can potentially treat a wide range of PKU patients. Sephience is approved in the United States, the European Economic Area (EEA), Japan, and other regions. Global DMD Franchise: This franchise includes two products for Duchenne muscular dystrophy (DMD), a rare and life-threatening disorder: Translarna (ataluren) and Emflaza (deflazacort). Translarna previously held conditional approval in the EEA. However, in March 2025, the European Commission (EC) adopted a negative opinion from the Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), leading to the non-renewal of Translarna's conditional marketing authorization for treating nonsense mutation Duchenne muscular dystrophy (nmDMD).

PTC Therapeutics, Inc. (NASDAQ:PTCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for PTCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PTCT spans 10-Q, 8-K.

Recent high-impact activity:

  • PTC Authorizes $500M Buyback With Stock Near 52-Week Low
  • PTC 10-Q Details $2.13B Cash, $29.0M Nine-Month Profit After $111M ST-920 Charge
  • PTC Q3 Revenue $358M, Full-Year Revenue Guidance Raised to $1.29-$1.32B
  • PTC Therapeutics Posts $51.7M Q3 Loss
  • PTC Therapeutics Strikes Asset Purchase Deal With Sangamo

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.73B
Net Income
$682.64M
Diluted EPS
$7.78
Op. Cash Flow
$711.2M
Free Cash Flow
$702.34M
Operating Income
$866.93M
Cash & Equivalents
$984.65M
Debt / Equity
0.00×
Net Margin
39.4%
Shares Outstanding
81.47M sh
Source: 10-K · filed 2026-02-19 · accession 0001104659-26-017575

Short Interest & Short Volume

7.50 days to cover

FINRA reported short interest of 7,779,250 shares in PTCT as of the October 30, 2026 settlement, a 6.3% decrease from the prior period — about 7.5 days to cover at its recent average daily volume. On November 20, 2026, 39.4% of PTCT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,779,250 shares as of October 30, 2026
Change vs prior period▼ 6.3%
Days to cover7.50 at avg daily volume of 1,037,445
Daily short volume (FINRA facilities)39.4% of 305,909 shares on November 20, 2026
5-day average short volume44.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$56.99 +1.01% today
52-week range · as of 2026-10-29 $56.99 – $90.87
Market cap
$4.71B
Volume
952.6K (0.9× avg)
3-mo avg 1M
Live data · 2026-11-22 05:32 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PTCT - Latest Insights

PTCT
Nov 03, 2026, 7:00 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $61.39
Real-time Price: $56.99 info
Change: -$4.40 (-7%) info
Market Cap: $4.714B info
PTCT
Oct 29, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $62.00
Real-time Price: $56.99 info
Change: -$5.01 (-8%) info
Market Cap: $4.714B info
PTCT
Oct 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $60.00
Real-time Price: $56.99 info
Change: -$3.01 (-5%) info
Market Cap: $4.714B info
PTCT
Oct 29, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $64.57
Real-time Price: $56.99 info
Change: -$7.57 (-12%) info
Market Cap: $4.714B info
PTCT
Aug 28, 2026, 5:42 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $70.09
Real-time Price: $56.99 info
Change: -$13.10 (-19%) info
Market Cap: $4.714B info
PTCT
Aug 28, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.09
Real-time Price: $56.99 info
Change: -$13.10 (-19%) info
Market Cap: $4.714B info
PTCT
Aug 13, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $73.60
Real-time Price: $56.99 info
Change: -$16.61 (-23%) info
Market Cap: $4.714B info
PTCT
Aug 12, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $72.64
Real-time Price: $56.99 info
Change: -$15.65 (-22%) info
Market Cap: $4.714B info
PTCT
Jul 30, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $75.49
Real-time Price: $56.99 info
Change: -$18.50 (-25%) info
Market Cap: $4.714B info
PTCT
Jul 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $77.01
Real-time Price: $56.99 info
Change: -$20.02 (-26%) info
Market Cap: $4.714B info
PTCT
Jul 30, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $77.87
Real-time Price: $56.99 info
Change: -$20.88 (-27%) info
Market Cap: $4.714B info
PTCT
Jun 18, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $78.42
Real-time Price: $56.99 info
Change: -$21.43 (-27%) info
Market Cap: $4.714B info
PTCT
Jun 18, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $78.42
Real-time Price: $56.99 info
Change: -$21.43 (-27%) info
Market Cap: $4.714B info
PTCT
Jun 16, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $76.77
Real-time Price: $56.99 info
Change: -$19.78 (-26%) info
Market Cap: $4.714B info
PTCT
Jun 15, 2026, 11:14 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $76.77
Real-time Price: $56.99 info
Change: -$19.78 (-26%) info
Market Cap: $4.714B info
PTCT
Jun 15, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $75.14
Real-time Price: $56.99 info
Change: -$18.15 (-24%) info
Market Cap: $4.714B info
PTCT
Jun 10, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $74.00
Real-time Price: $56.99 info
Change: -$17.01 (-23%) info
Market Cap: $4.714B info
PTCT
May 07, 2026, 5:25 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $69.95
Real-time Price: $56.99 info
Change: -$12.96 (-19%) info
Market Cap: $4.714B info
PTCT
May 07, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $69.29
Real-time Price: $56.99 info
Change: -$12.30 (-18%) info
Market Cap: $4.714B info
PTCT
May 07, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $69.95
Real-time Price: $56.99 info
Change: -$12.96 (-19%) info
Market Cap: $4.714B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets